SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company.
Analysts’ downgrades for Wednesday, June 1st: Build-A-Bear Workshop (NYSE:BBW) was downgraded by analysts at StockNews.com from a buy rating to a hold rating. Bunge (NYSE:BG) was downgraded by analysts at StockNews.com from a buy rating to a hold rating. Brookdale Senior Living (NYSE:BKD) was downgraded by analysts at StockNews.com from a hold rating to a […]
Cortexyme (NASDAQ:CRTX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The company’s drug candidate […]